What if the risk–benefit calculation was fundamentally misrepresented?
A recent review published by TrialSite News — “Adverse Health Effects of COVID-19 Vaccines: An Updated Review of the PubMed Literature” — does not tiptoe around the issue.
It reaches a blunt and deeply controversial conclusion.
Based on its review of the published literature and publicly available safety reporting data, the authors argue that the mRNA COVID vaccines should have been reconsidered — and potentially withdrawn — once serious adverse event signals became clear and effectiveness against infection waned.
That is not a minor adjustment to the official narrative.
It is a direct challenge to it.
The Risk–Benefit Claim at the Centre
The article makes a specific and striking assertion regarding cost–benefit balance.
It states:
“The number of people from the US who died following Covid-19 vaccination so far is 19,590 (according to the latest VAERS report). Thus, the Cost/Benefit ratio is approximately 19,590/600, or ~32.7. That number ideally should be a fraction of a percent for people who get vaccinated.”
In other words, the authors argue that the estimated number of vaccine-associated deaths reported to the U.S. adverse event reporting system far exceeded the number of lives they calculate were saved in the United States during the relevant period — producing what they consider an unacceptable cost–benefit ratio.
They go even further:
“If the health bureaucrats had provided the real-world death statistics for Covid-19 and for the Covid-19 vaccines, there would have been no emergencies, no need to rush vaccine development by cutting corners…”
That is an extraordinary claim.
It suggests not just miscalculation — but systemic overstatement of threat and benefit.
What the Review Looked At
The article surveyed published studies indexed in PubMed, alongside post-marketing safety data and adverse event reporting systems.
It examined:
Phase 3 trial results
Post-licensure safety monitoring
Observational effectiveness studies
Research on waning immunity
Reports of myocarditis, thrombotic events and other serious reactions
The core argument is that while early trial data showed short-term efficacy against symptomatic disease, real-world effectiveness declined, boosters became necessary, and safety signals accumulated.
In that context, the authors argue the continuation of mass vaccination — particularly in lower-risk populations — should have been reassessed far earlier.
The Controversy
It must be said plainly:
VAERS is a passive reporting system and does not in itself establish causation. Reports do not automatically equal confirmed vaccine-caused deaths.
However, the article’s contention is that when safety signals reach a certain magnitude, the burden shifts. The question becomes not “Can we prove every case?” but “Have we transparently evaluated whether the overall balance remains justified?”
That evaluation, the authors argue, never truly happened in public view.
The Larger Failure
Whether one agrees with the article’s modelling or not, its broader indictment is hard to dismiss:
Emergency authorisations were granted at unprecedented speed.
Risk communication was absolute rather than nuanced.
Dissent was marginalised rather than debated.
Withdrawal thresholds were never clearly defined.
And crucially, there has been no independent, comprehensive inquiry into the totality of the decisions made.
Why This Matters
There will be another pandemic.
If the risk–benefit calculations were misjudged…
If adverse event data were insufficiently scrutinised…
If urgency was amplified beyond proportional threat…
Then failing to investigate now guarantees repetition later.
Science is not protected by avoiding hard questions.
It is protected by confronting them.
If the vaccines were overwhelmingly beneficial, a transparent inquiry would confirm it.
If the balance was miscalculated, the public deserves to know that too.
Because the next emergency will demand trust.
And trust cannot survive unanswered questions.
